Tuesday, May 23, 2017 7:36:23 PM
Regarding his analysis of the lipid drug, he mentions that the reduction in triglycerides weren't statistically significant for the lower dose. That completely ignores the magnitude of reduction though. Tiny effect sizes in tiny populations with tiny p values... this is absolutely not the case. It just missed the p value cutoff, and likely only because of the trial size. They literally showed 75%+ triglyceride reduction at the highest dose, that's insane. The p value missed in the mid range on a nearly 40% triglyceride reduction. And he then gripes that they are using a 10 mg dose for the trials, and implies they aren't going to be analyzing triglycerides because he can't find it in the study brief on the FDA site. So he obviously did not listen to the conference call. If they didn't reduce the dose cutoff to 10 mg, who knows what on earth the new trial would have shown. It's one thing to reduce someone's triglycerides 80% if they have a severe hereditary disease associated with triglyceride accumulation. Reduce normal people with run of the mill high lipids, cutting their triglycerides by 80%... we have no idea what effect that would have on a common person metabolically. A lot of these pathways interact and have circuit breakers. Bodies do strange things sometimes to compensate. It's territory we don't need to be treading into. The study size for our phase two will easily meet p value if they powered it correctly, now that more patients are being studied. Again, it's the only sane way to be approaching the trial. I don't expect him to know that stuff, but I also don't expect him to be talking about p values and pretending to know what they translate to in terms of clinical significance, so I was disappointed in that regard.
Either way, in the world I was raised in, any press is good press. We are unknown. Even half hearted bash pieces, if negative, are still free advertising that we are out there. The more press we get before data, bad or not, the better positioned we will be to move on good data.
I also think he missed the mark on needing to dilute after results. He made no mention of their ATM arrangement, completely disregarded it. Yeah, dilution is possible... but it defies logic to see the company make it this far preserving insider ownership and utilizing less dilutive measures to operate, and to expect them to begin operating like every other crippled start up biotech.
He hit the mark though, with his target audience. If you know nothing about SARMs and lipids, you should stay out until they have data in hand. His advice to buy after news ignores the low float. My hope is that this will be a tough stock to chase on good news.
The article gave me a good excuse to review the old trials and data though! So not a total loss. I won't be losing any sleep over it though.
Recent VKTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2024 01:20:57 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2024 08:29:51 PM
- Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 11:23:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:13:31 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:05:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 09:56:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 09:55:09 PM
- Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% • IH Market News • 07/25/2024 10:19:48 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/24/2024 09:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:10:08 PM
- Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 07/24/2024 08:05:00 PM
- US Index Futures Fall Amid Tech Giant Earnings, Oil Prices Rise • IH Market News • 07/24/2024 09:55:54 AM
- Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:05:00 PM
- Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association • PR Newswire (US) • 06/24/2024 11:33:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:10:11 AM
- Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) • PR Newswire (US) • 06/04/2024 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 08:03:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/22/2024 09:12:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/22/2024 08:33:26 PM
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/24/2024 08:05:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM